merk-m-logo-blue





CELEBRATING

10 Years of Breakthroughs in Organoid Technology 

Over the past 10 years, we've decoded the dynamics of adult stem cells, optimized organoid culture conditions, established a vast biobank of patient-derived organoids spanning various diseases and tissue types, and introduced groundbreaking readouts and assays revealing the complex interactions between tumors and the immune system.

In honor of the extraordinary breakthroughs that have played a pivotal role in closing the gap between the lab and the clinic, we extend a warm invitation to partake in our festivities commemorating this revolutionary decade. 

Join us in the celebrations now!

An impressive array of scientific insights

ON DEMAND WEBINAR

10 years of breakthroughs in Organoid Technology: from adult stem cell discovery to changing patients’ lives

6th September 2023 | ONLINE

watch now

PANEL DISCUSSION

Conversation with the pioneers: unveiling breakthroughs in Organoid Technology

28th September 2023 | ONLINE

watch now

EXCLUSIVE INTERVIEW 

Conversation with our CEO: A 10-year journey of advancements in Organoid Technology

watch now




Explore our journey so far

2009

First organoid generated from mouse intestine

2011

First human organoid developed from intestinal epithelium

2013

Hubrecht Organoid Technology Foundation was established to upscale and commercialize organoid technology

2015

First cystic fibrosis patient treated based on organoid data

2017

HIT-CF validation trial launched

2018

First oncology clinical candidate entirely developed using organoid screening approved for clinical trials

2022

Expansion of lab facilities

2023

Hubrecht Organoid Technology becomes HUB Organoids B.V.

Dive deeper into organoid technology

ORGANOID TECHNOLOGY

Single Lgr5 stem cell build crypt-villus structures in vitro without a mescenchymal niche

Nature | May 2009

read now

ONCOLOGY

First clinical candidate developed using HUB Organoids in five years 

Case study

download now

ORGANOID TECHNOLOGY

The FDA Modernization Act 2.0: A patient-centric paradigm shift in drug development

Blog

read more